Document is current
Any future updates will be listed below
-
Authors
Gibble, Theresa Hunter https://orcid.org/0000-0001-8412-9175
Stassek, Larissa
Harding, Gale
Stefan, Marissa
Fikre, Tsion
Bleakman, Alison Potts
Moses, Richard
Dubinsky, Marla
-
Funding
Funding for this research was provided by:
Eli Lilly and Company (Eli Lilly and Company)
- License Information
-
More Information
Article History
Received: 20 March 2024
Accepted: 17 October 2024
First Online: 12 November 2024
Declarations
:
: All participants provided electronic or written informed consent prior to their interview. The study protocol and recruiting clinical sites were approved by Advarra (Columbia, MD), a central institutional review board (study reference number: Pro00069827).
: Not applicable.
: T.H.G., A.P.B., and R.M. are employees and shareholders of Eli Lilly and Company. L.S., G.H., M.S., and T.F. are employees of Evidera, which received funding from Eli Lilly and Company to conduct this research. M.D. is a consultant/advisor for Abbvie, Abivax, Arena Pharmaceuticals, Astra Zeneca, Boehringer Ingelheim International GmbH, Bristol-Meyer Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech Inc, Gilead, Janssen Pharmaceuticals, Merck, Pfizer Inc, Prometheus Biosciences, and Takeda Pharmaceuticals.
